However, considerable evidence has demonstrated that EGFR blockade, or inhibition of other receptor systems such as HER2, MET and IGF-IR leads to enhanced or re-activated STAT3 activity and subsequent continued tumor progression [24,25]. This evidence concerns the gene ERBB2 and neoplasm.